Drug Profile
KT 2962
Alternative Names: KT2 962Latest Information Update: 05 Dec 2007
Price :
$50
*
At a glance
- Originator Kotobuki Seiyaku
- Class Antiplatelets; Small molecules
- Mechanism of Action Free radical scavengers; Thromboxane A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Cerebrovascular disorders; Coronary thrombosis; Migraine; Reperfusion injury; Thrombosis
Most Recent Events
- 02 Nov 2005 No development reported - Preclinical for Reperfusion injury in Japan (unspecified route)
- 01 Apr 2003 Preclinical trials in Reperfusion injury in Japan (unspecified route)
- 02 Oct 1997 Phase-I clinical trials for Asthma in Japan (PO)